Comparison of efficacy of three different anti-vascular endothelial growth factor agents in treatment of macular edema secondary to branch retinal vein occlusion

Poster Details

First Author: H.Kaldırım TURKEY

Co Author(s):                                 

Abstract Details


To compare the efficacy of intravitreal bevacizumab, ranibizumab and aflibercept treatments for macular edema following branch retinal vein occlusion (BRVO).


Bagcilar Training and Research Hospital


Totally 69 eyes of 69 patients with macular edema secondary to non-ischaemic BRVO were retrospectively reviewed. Totally 27 patients received PRN (Pro-Re-Nata) intravitreal bevacizumab 1.25mg/0.05mL, 22 patients treated by PRN intravitreal ranibizumab 0,5mg/0.05 mL, and 20 patients treated by PRN intravitreal aflibercept 2mg/0.05 mL were included in the study. All patients were followed up monthly period after treatment, with anterior segment and fundus examination and best corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) measurements. The 1st, 3rd, 6th, 9th and 12th examination findings were compared .


Although, there were not any statistically significant alterations in pretreatment values of BCVA, IOP or CMT among groups, BCVA was significantly better in ranibizumab and aflibercept groups, compared with the bevacizumab group in 6th month of follow-up. Similarly, CMT was significantly lower in ranibizumab and aflibercept groups, at 6th month of follow-up. Regarding 12th month results of BCVA, IOP and CMT values, there was not any statistically significant difference between groups. The mean injection number was statistically significantly the highest in bevacizumab group and the lowest in aflibercept group compared with other groups.


Although at 6th month of follow-up ranibizumab and aflibercept groups had better results in BCVA and CMT values, there were not any significant differences between 3 groups at the end of 12th month. On the otherhand, total injection number was significantly lower in aflibercept group than other 2 groups. Larger studies with longer follow-up periods are warranted to define the clinical differences of those commonly used anti-VEGF agents regarding not only efficacy but also the number of injections required.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy